Organon & Co.

After the speaker's remarks, there will be a question and answer session. During that time, you can simply press star 1 on your telephone keypad to ask a question and star 1 on your telephone keypad to withdraw from the queue. As a reminder, this call is being recorded. Thank you. I would now like to turn the call over to Jennifer Holchak, Vice President, Investor Relations.

Please begin your conference. Thank you, operator, and good morning, everyone.

Thank you for joining Organon's third quarter 2023 earnings call. With me today are Kevin Ali, Organon's chief executive officer, who will cover strategy and operational highlights, and Matt Walsh, our chief financial officer, who will review performance and guidance. Dr. Sandra Milligan, Organon's head of R&D, will also be joining us for the Q&A portion of this call. Today, we will be referencing a presentation that will be visible during this call for those of you on your webcast. The presentation will also be available following this call on the events and presentation section of our Organon Investor Relations website at www.organon.com. Before we begin, I would like to remind listeners that certain information discussed by management during this conference call will include forward-looking statements. Actual results could differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the company's business. which are discussed in the company's filings with the Securities and Exchange Commission, including our 10-K and subsequent periodic filings. In addition, we will discuss certain non-GAAP financial measures on this call, which should be considered a supplement to and not a substitute for financial measures prepared in accordance with GAAP. A reconciliation of these non-GAAP measures to the comparable GAAP measures is included in the press release and conference call presentation. I would now like to turn the call over to our CEO, Kevin Ali.